Text Size

Drug Treatment for Pathological Gambling

This study has been completed.
Sponsor:
Information provided by:
National Institute of Mental Health (NIMH)
ClinicalTrials.gov Identifier:
NCT00055393
First received: February 28, 2003
Last updated: February 15, 2008
Last verified: February 2008
History of Changes
  Purpose

This study will determine whether the drug bupropion is an effective treatment for Pathological Gambling.


Condition Intervention
Gambling
 Drug: Bupropion

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Bupropion Versus Placebo in the Treatment of Pathological Gambling

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute of Mental Health (NIMH):

Estimated Enrollment: 80
Study Start Date: July 2002
Study Completion Date: April 2006
Estimated Primary Completion Date: May 2005 (Final data collection date for primary outcome measure)
Detailed Description:

As gambling opportunities proliferate, PG has become a major health concern. Despite its importance, few treatment options with proven efficacy exist. This study will attempt to identify an effective treatment for PG.

Participants are randomly assigned to receive either bupropion or placebo for 12 weeks. Participants are assessed at baseline and at Weeks 2, 3, 4, 5, 6, 8, 10, and 12. Self administered questionnaires and interviews are used to assess participants. Follow-up assessments are made 1, 3, and 6 months after study completion.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • PG for at least 1 year
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00055393

Locations
United States, Iowa
Roy J. and Lucille A. Carver College of Medicine, University of Iowa
Iowa City, Iowa, United States, 52242
Sponsors and Collaborators
National Institute of Mental Health (NIMH)
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00055393     History of Changes
Other Study ID Numbers: R21 MH63289, DSIR AT-AS
Study First Received: February 28, 2003
Last Updated: February 15, 2008
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Gambling
Impulse Control Disorders
Mental Disorders
Bupropion
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
 Therapeutic Uses
Pharmacologic Actions
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on May 16, 2013